Advertisement

Clinical Trials using Monoclonal Antibodies

  • John W. Smith
  • Dan L. Longo

Abstract

Early attempts at passive immunotherapy by administering natural antisera derived from recovered cancer patients to patients with active disease failed to result in significant antitumor responses. Many of the limitations of this serotherapy were remedied by the revolutionary innovation described by Kohler and Milstein (1) of monoclonal antibody production by means of hybridoma technology. Large quantities of homogeneous, highly specific antibody to a defined antigenic determinant became available for clinical trials. Most monoclonal antibodies (mAbs) used to date to treat cancer patients have been murine mAbs. Recently, clinical grade human mAbs have been generated in sufficient quantity to permit investigation.

Keywords

Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Murine Monoclonal Antibody Antigenic Modulation Common Acute Lymphoblastic Leukemia Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. Kohler and C. Milstein, Continuous culture of fused cells secreting antibody of predefined specificity. Nature (London) 256: 495–497 (1975).CrossRefGoogle Scholar
  2. 2.
    J. Schlom, Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 46: 3225–3238 (1986).PubMedGoogle Scholar
  3. 3.
    A.A. Epenetos, D. Snook, H. Durbin, et al., Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46: 3183–3191 (1986).PubMedGoogle Scholar
  4. 4.
    B.C. Ward, S.J. Mather, J.H. Shepard, et al., Localization of intraperitoneally injected 125I-HMFG2 in patients with ovarian cancer. Lancet ii: 580–581 (1986) (letter).Google Scholar
  5. 5.
    H. Koprowski, D. Herlyn, M. Lübeck, et al., Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. U.S.A. 81: 216–219 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    R.O. Dillman, J.C. Beauregard, S.E. Halpern, et al., Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J. Biol. Response Mod. 5: 73–84 (1986).PubMedGoogle Scholar
  7. 7.
    A.F. Lobuglio, M. Saleh, L. Peterson, et al., Phase I clinical trial of CO 17-lA monoclonal antibody. Hybridoma 5: 5117–5123 (1986).Google Scholar
  8. 8.
    J. Ritz, J.M. Pesando, S.E. Sallan, et al., Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141–152 (1981).PubMedGoogle Scholar
  9. 9.
    R.O. Dillman, D.L. Shawler, R.E. Sobol, et al., Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59: 1036–1045 (1982).PubMedGoogle Scholar
  10. 10.
    R.A. Miller and R. Levy, Response of cutaneous T-cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet ii: 226–230 (1981).Google Scholar
  11. 11.
    R.A. Miller, A.R. Oseroff, P.T. Stratte, et al., Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988–995 (1983).PubMedGoogle Scholar
  12. 12.
    R.O. Dillman, D.L. Shawler, J.B. Dillman, et al., Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with TlOl monoclonal antibody. J. Clin. Oncol. 2: 881–891 (1984).PubMedGoogle Scholar
  13. 13.
    K.A. Foon, R.W. Schroff, P.A. Bunn, et al., Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64: 1085–1093 (1984).PubMedGoogle Scholar
  14. 14.
    R.O. Dillman, J. Beauregard, D.L. Shawler, et al., Continuous infusion of TlOl monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. Biol. Response Mod. 394–410 (1986).Google Scholar
  15. 15.
    J.H. Bertram, P.S. Gill, A.M. Levine, et al., Monoclonal antibody TlOl in T-cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood 68: 752–761 (1986).PubMedGoogle Scholar
  16. 16.
    R.A. Miller, D.G. Maloney, R. Warnke, et al., Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. Med. 306: 517–522 (1982).CrossRefGoogle Scholar
  17. 17.
    T.C. Meeker, J. Lowder, D.G. Maloney, et al., A clinical trial of antiidiotype therapy for B-cell malignancy. Blood 65: 1349–1363 (1985).PubMedGoogle Scholar
  18. 18.
    J.N. Lowder, T.C. Meeker, M. Campbell, et al., Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: Correlation with clinical responses. Blood 69; 199–210 (1987).PubMedGoogle Scholar
  19. 19.
    T.A. Waldmann, D.L. Longo, W.J. Leonard, et al., Interleukin 2 receptor (Tac antigen) expression in HTLV-l-associated adult T-cell leukemia. Cancer Res. (Suppl.) 45:4559S-4562S (1985).PubMedGoogle Scholar
  20. 20.
    R.A. Riesfield and M.I. Greeve, Fifth Annual Sapporo Cancer Seminar-Meeting Report. Cancer Res. 2193–2196 (1986).Google Scholar
  21. 21.
    L.M. Nadler, L. Botnick, R. Finberg, et al., Anti-Bl monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet ii; 427–430 (1984).CrossRefGoogle Scholar
  22. 22.
    W. Heit, D. Bumjes, M. Wiesneth, et al., Ex vivo T-Cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-vs-host disease in allogeneic bone marrow transplantation. J. Haematol. 64: 479–486 (1986).CrossRefGoogle Scholar
  23. 23.
    P.J. Martin, J.A. Hansen, C.D. Buckner, et al., Effects of in vitro depletion of T cells in HLA — Identical allogeneic marrow grafts. Blood 66: 664–672 (1985).PubMedGoogle Scholar
  24. 24.
    H.F. Sears, J. Mattis, D. Herlyn, et al., Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1: 762–765 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    H.F. Sears, D. Herlyn, Z. Steplewski, et al., Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J. Biol. Resp. Mod. 3: 138–150 (1984).Google Scholar
  26. 26.
    J.W. Shen, B. Atkinson, H. Koprowski, et al., Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int. J. Cancer 33: 465–468 (1984).PubMedCrossRefGoogle Scholar
  27. 27.
    H.F. Sears, D. Herlyn, Z. Steplewski, et al., Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 45: 5910–5913 (1985).PubMedGoogle Scholar
  28. 28.
    H.F. Sears, D. Herlyn, Z. Spteplewski, et al., Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma 5: 5109–5115 (1986).Google Scholar
  29. 29.
    W.F. Sindelar, M.M. Maher, D. Herlyn, et al., Trial of therapy with monoclonal antibody 17-lA in pancreatic carcinoma; Preliminary results. Hybridoma 5: 5125–5132 (1986).Google Scholar
  30. 30.
    M.A. Tempero, P.M. Pour, E. Uchida, et al., Monoclonal antibody CO17–1A and leukopheresis in immunotherapy of pancreatic cancer. Hybridoma 5: 5133–5138 (1986).Google Scholar
  31. 31.
    J.Y. Douillard, P.A. Lehur, J. Vignoud, et al., Monoclonal antibodies specific immuntherapy of gastrointestinal tumors. Hybridoma 5: 5139-5149 (1986).Google Scholar
  32. 32.
    J. Frodin, P. Biberfield, B. Christensson, et al., Treatment of patients with metastasizing colorectal carcinoma with mouse monoclonal antibodies (Moab 17-lA): A progress report. Hybridoma 5: 5151–5161 (1986).Google Scholar
  33. 33.
    A.R. Paul, P.F. Engstrom, L.M. Weiner, et al., Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-lA murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin, and mitomycin (FAM). Hybridoma 5: 5171–5174 (1986).Google Scholar
  34. 34.
    H. Verrill, M. Goldberg, R. Rosenbaum, et al., Clinical trial of Wistar Institute 17-lA monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: A preliminary report. Hybridoma 5: 5175-5183 (1986).Google Scholar
  35. 35.
    L.M. Weiner, Z. Steplewski, H. Koprowski, et al., Biologic effects of gamma interferon pretreatment followed by monoclonal antibody 17-lA administration in patients with gastrointestinal carcinoma. Hybridoma 5: 565–577 (1986).Google Scholar
  36. 36.
    R.K. Oldham, K.A. Foon, A.C. Morgan, et al., Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. Clin. Oncol. 2: 1235–1244 (1984).Google Scholar
  37. 37.
    A. Knuth, Response to monoclonal antibodies in melanoma: Specific or nonspecific? Eur. J. Cancer Clin. Oncol. 22: 1285–1288 (1986).PubMedCrossRefGoogle Scholar
  38. 38.
    A.N. Houghton, D. Mintzer, C. Cordon-Cardo, et al., Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. 82: 1242–1246 (1985).PubMedCrossRefGoogle Scholar
  39. 39.
    R.F. Irle and D.L. Morton, Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. 83: 8694–8698 (1986).CrossRefGoogle Scholar
  40. 40.
    L. Spitler, Phase I trial of monoclonal anti-melanoma antibody ricin A chain immunotoxin. Clin. Cancer Lett.9: 1–2 (1986).Google Scholar
  41. 41.
    L. Spitler, personal communication.Google Scholar
  42. 42.
    S.M. Larson, J.A. Carrasquillo, K.A. Krohn, et al., Localization of 131 I-labeled p 97-specific Fab fragments in human melanoma as a basis for radiotherapy. Clin. Invest. 72: 2101–2114 (1983).CrossRefGoogle Scholar
  43. 43.
    J.A. Carrasquillo, K.A. Krohn, P. Beaumier, et al., Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat. Rep. 68: 317–328 (1984).PubMedGoogle Scholar
  44. 44.
    S.M. Larson, Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J. Nucl. Med. 26: 538–545 (1985).PubMedGoogle Scholar
  45. 45.
    J.A. Carrasquillo, personal communication.Google Scholar
  46. 46.
    S.T. Rosen, A.M. Zimmer, R.G. Leikin, et al., Radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphomas utilizing an 131I-labeled TlOl monoclonal antibody: An Illinois Cancer Council Study. Blood 68: 241a (1986) (Abstract).Google Scholar
  47. 47.
    N. Courtenay-Luck, A.A. Epenetos, K.E. Hainan, et al., The Hammersmith Oncology Group and the Imperial Cancer Research Fund. Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment. Lancet i: 1441–1443 (1984).Google Scholar
  48. 48.
    A.A. Epenetos, N. Courtenay-Luck, D. Pickering, et al., Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Med. J. 290: 1463–1466 (1985).CrossRefGoogle Scholar
  49. 49.
    D. Pectasides, S. Stewart, N. Courtenay, et al., Antibody guided irradiation of malignant pleural and pericardial effusions. Br. J. Cancer 53: 727–732 (1986).PubMedCrossRefGoogle Scholar
  50. 50.
    A.A. Epenetos, G. Hooker, T. Krausy, et al., Antibody guided irradiation of malignant ascites in ovarian cancer: A new therapeutic method possessing specificity against cancer cells. Obstet. Gynecol. 68: 715–745 (1986).Google Scholar
  51. 51.
    A.A. Epenetos, Clinical results with regional antibody-guided irradiation. Cancer Drug Deliv. 2: 233 (1985).Google Scholar
  52. 52.
    J.W. Greiner, P.H. Hand, P. Noguchi, et al., Enhanced expression of surface tumor associated antigens on human breast and colon tumor cells after recombinant human leukocyte gamma-interferon treatment. Cancer Res. 44: 3208–3214 (1984).PubMedGoogle Scholar
  53. 53.
    L.K. Sun, P. Curtis, E. Radkowicz-Szukzynska, et al., Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-lA. Proc. Natl. Acad. Sci. (U.S.A.) 84: 214–218 (1987).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • John W. Smith
    • 1
  • Dan L. Longo
    • 1
  1. 1.Biological Response Modifiers Program, Division of Cancer TreatmentNational Cancer InstituteFrederickUSA

Personalised recommendations